BLOG
2022 Letter From The CEO
2022 Letter From The CEO Written-by: Sumeet Singh, Chief Executive Officer As we near 2023, I want to reflect on this past year and the massive changes we have seen across the industry and for Pharma Solutions ourselves. We have seen massive catalysts for change with...
Recent Articles
How Puerto Rico’s New License Requirement Affects Industry
How Puerto Rico’s New License Requirement Affects Industry Written-by: Sumeet Singh, CEO Pharma Solutions has received updates from the Puerto Rico...
Review of FDA July 2022 DSCSA Draft Guidance on Identifying Trading Partners
Review of FDA July 2022 DSCSA Draft Guidance on Identifying Trading Partners Written-by: Sumeet Singh, CEO As we rocket towards the Event Horizon of...
Part 4: Macro-Insights for Industry
Part 4: Macro-Insights for Industry Written-by: Sumeet Singh, CEO 5 Macro-Insights for Industry The FDA Proposed Rules are poised to have sweeping...
Breaking News: Puerto Rico Begins Immediate Enforcement of their Non-Resident State License Requirement
Breaking News: Puerto Rico Begins Immediate Enforcement of their Non-Resident State License Requirement Written-by: Sumeet Singh, CEO Puerto Rico...
NABP Temperature Validation Studies
NABP Temperature Validation Studies Written-by: Sumeet Singh, CEO For all entities that are applying for NABP’s Drug Distributor Accreditation, or...
Are you ready for Butalbital/APAP combination products to become a Controlled Substance?
Are you ready for Butalbital/APAP combination products to become a Controlled Substance? Written-by: Deneen Fumich, RPh On April 12, 2022, the Drug...
